A carregar...
Implementing Levodopa‐Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners
BACKGROUND: Levodopa‐carbidopa intestinal gel (LCIG, designated in the United States as carbidopa‐levodopa enteral suspension, CLES) was approved in the United States in 2015 for the treatment of refractory motor fluctuations in individuals with Parkinson disease (PD). Many neurologists in the Unite...
Na minha lista:
| Publicado no: | Mov Disord Clin Pract |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6174493/ https://ncbi.nlm.nih.gov/pubmed/30363427 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mdc3.12630 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|